Mechanisms of Vein Graft Adaptation to the Arterial Circulation - Insights Into the Neointimal Algorithm and Management Strategies

被引:122
作者
Muto, Akihito [1 ,2 ]
Model, Lynn [1 ,2 ]
Ziegler, Kenneth [1 ,2 ]
Eghbalieh, Sammy D. D. [1 ,3 ]
Dardik, Alan [1 ,2 ,4 ]
机构
[1] Yale Univ, Sch Med, Interdept Program Vasc Biol & Therapeut, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Vasc Surg Sect, New Haven, CT 06520 USA
[3] St Marys Hosp, Waterbury, CT USA
[4] VA Connecticut Healthcare Syst, West Haven, CT USA
关键词
Adaptation; Eph-B4; Nogo-B; Vein grafts; Veins; SMOOTH-MUSCLE-CELLS; FIBROBLAST-GROWTH-FACTOR; COAGULATION-FIBRINOLYSIS SYSTEM; ATTENUATES INTIMAL HYPERPLASIA; RAPAMYCIN INHIBITS RELEASE; INTERNAL MAMMARY ARTERY; MEDIATED GENE-TRANSFER; NECROSIS-FACTOR-ALPHA; KAPPA-B DECOY; SAPHENOUS-VEIN;
D O I
10.1253/circj.CJ-10-0495
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
For patients with coronary artery disease or limb ischemia, placement of a vein graft as a conduit for a bypass is an important and generally durable strategy among the options for arterial reconstructive surgery. Vein grafts adapt to the arterial environment, and the limited formation of intimal hyperplasia in the vein graft wall is thought to be an important component of successful vein graft adaptation. However, it is also known that abnormal, or uncontrolled, adaptation may lead to abnormal vessel wall remodeling with excessive neointimal hyperplasia, and ultimately vein graft failure and clinical complications. Therefore, understanding the venous-specific pathophysiological and molecular mechanisms of vein graft adaptation are important for clinical vein graft management. Of particular importance, it is currently unknown whether there exist several specific distinct molecular differences in the venous mechanisms of adaptation that are distinct from arterial post-injury responses; in particular, the participation of the venous determinant Eph-B4 and the vascular protective molecule Nogo-B may be involved in mechanisms of vessel remodeling specific to the vein. This review describes (1) venous biology from embryonic development to the mature quiescent state, (2) sequential pathologies of vein graft neointima formation, and (3) novel candidates for strategies of vein graft management. Scientific inquiry into venous-specific adaptation mechanisms will ultimately provide improvements in vein graft clinical outcomes. (Circ J 2010; 74: 1501-1512)
引用
收藏
页码:1501 / 1512
页数:12
相关论文
共 124 条
[1]   A new role for Nogo as a regulator of vascular remodeling [J].
Acevedo, L ;
Yu, J ;
Erdjument-Bromage, H ;
Miao, RQ ;
Kim, JE ;
Fulton, D ;
Tempst, P ;
Strittmatter, SM ;
Sessa, WC .
NATURE MEDICINE, 2004, 10 (04) :382-388
[2]   Molecular control of arterial-venous blood vessel identity [J].
Adams, RH .
JOURNAL OF ANATOMY, 2003, 202 (01) :105-112
[3]  
Adkins JR, 2004, AM SURGEON, V70, P384
[4]  
ALBINSSON S, 2010, ARTERIOSCLER TH 0408
[5]  
Alexander JH, 2005, JAMA-J AM MED ASSOC, V294, P2446
[6]   Directed migration of smooth muscle cells to engineer plaque-resistant vein grafts [J].
Amabile, PG ;
Wang, DS ;
Kao, EY ;
Lee, J ;
Elkins, CJ ;
Yuksel, E ;
Hilfiker, PR ;
Waugh, JM ;
Dake, MD .
JOURNAL OF ENDOVASCULAR THERAPY, 2005, 12 (06) :667-675
[7]   An external, oversized, porous polyester stent reduces vein graft neointima formation, cholesterol concentration, and vascular cell adhesion molecule 1 expression in cholesterol-fed pigs [J].
Angelini, GD ;
Lloyd, C ;
Bush, R ;
Johnson, J ;
Newby, AC .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2002, 124 (05) :950-956
[8]   Controlled release of small interfering RNA targeting midkine attenuates intimal hyperplasia in vein grafts [J].
Banno, Hiroshi ;
Takei, Yoshifumi ;
Muramatsu, Takashi ;
Komori, Kimihiro ;
Kadomatsu, Kenji .
JOURNAL OF VASCULAR SURGERY, 2006, 44 (03) :633-641
[9]   NITRIC-OXIDE AND PROSTACYCLIN - DIVERGENCE OF INHIBITORY EFFECTS ON MONOCYTE CHEMOTAXIS AND ADHESION TO ENDOTHELIUM INVITRO [J].
BATH, PMW ;
HASSALL, DG ;
GLADWIN, AM ;
PALMER, RMJ ;
MARTIN, JF .
ARTERIOSCLEROSIS AND THROMBOSIS, 1991, 11 (02) :254-260
[10]  
BONAUER A, 2010, CURR DRUG TARGE 0426